Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/47332
Title: Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer
Authors: Morales, Manuel
Santana, Norberto 
Soria, Adela
Mosquera, Alicia
Ordovás, José
Nóvoa, Javier
Betancor, Pedro
Valerón, Pilar F. 
Díaz-Chico, Bonifacio 
Chirino, Ricardo 
Keywords: Density-Lipoprotein Subclasses
Cardiovascular Risk-Factors
Myocardial-Infarction
Adjuvant Tamoxifen
Plasma-Lipids
Women
Therapy
Lp(A)
Disease
Trial
Issue Date: 1996
Publisher: 0167-6806
Journal: Breast Cancer Research and Treatment 
Abstract: Serum lipids and apolipoprotein levels were measured in twenty postmenopausal women with primary breast cancer, before and three months after tamoxifen therapy (10 mg twice a day). Tamoxifen caused a significant reduction in total serum cholesterol (10%; P < 0.02), and in low-density lipoprotein cholesterol (17%: P < 0.01), and a significant 47% increase in the subclass 2 of the high density lipoprotein cholesterol (P < 0.01). In addition, tamoxifen caused a 16% increase in apolipoprotein A-I, a 12% decrease in apolipoprotein B (P < 0.05), and a 37% reduction in the serum concentration of lipoprotein(a) (P < 0.01). These results show that tamoxifen brings about an important improvement in serum lipid profile.
URI: http://hdl.handle.net/10553/47332
ISSN: 0167-6806
DOI: 10.1007/BF01806815
Source: Breast Cancer Research and Treatment[ISSN 0167-6806],v. 40, p. 265-270
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

32
checked on Feb 21, 2021

WEB OF SCIENCETM
Citations

33
checked on Feb 21, 2021

Page view(s)

18
checked on Feb 22, 2021

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.